PF-08046054 by Pfizer for Solid Tumor: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Solid Tumor.

Extended Paxlovid courses show mixed results for long COVID symptoms

A study indicates that longer Paxlovid treatments could improve long COVID symptoms in some patients, highlighting the need for tailored antiviral strategies.

January 8, 2025

Dietary Thiamine Linked With Cognition

Dietary thiamine (vitamin B1) intake was linked with cognition in older adults, a longitudinal analysis in China suggested. Over a median follow-up of 5.9 years,

February 21, 2024

Sage suffers pipeline setback with failure of drug to treat essential tremor

Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in patients with a neurological condition called essential tremor. The negative

July 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.